Skip to content

Fish Oil in pREgnancY for Personalized Prevention of Early Childhood Asthma

Fish Oil in pREgnancY for Personalized Prevention of Early Childhood Asthma (FREYA)

Status
Recruiting
Phases
Phase 3
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT06560255
Acronym
FREYA
Enrollment
2000
Registered
2024-08-19
Start date
2024-12-20
Completion date
2033-03-31
Last updated
2025-09-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Allergy, Asthma, Cognition Disorders in Children, Croup, Development, Child, Eczema, Fractures, Bone, Gastrointestinal Infection, Psychiatric Diagnosis, Respiratory Tract Infections, Wheezing

Keywords

Childhood, Asthma, Infections, Eczema, Allergy, Development, Psychiatry, Bone development, Cognition, Growth

Brief summary

The overall aim of the study is to develop a nutritional preventive fish oil supplementation strategy in pregnancy for early childhood asthma/persistent wheeze during the first three years of life as we hypothesize that both supplementations in higher doses than recommended could reduce the risk of disease development.

Detailed description

Randomization of 2000 pregnant women to fish oil of 2.4 g/day (55% EPA and 37% DHA) in triacylglycerol form vs placebo. Supplementation begins in gestational week 24 (22-26) until 1 week after delivery. Allocation to the trial will be determined based on the pre-interventional maternal blood levels of EPA+DHA with a dried blood screening test. Women with low levels (below 4.7% of total fatty acids) will be assigned to the fish oil RCT. Maternal blood will be used for genetic, metabolomic and proteomic profiling. A 3-year follow-up of the children with longitudinal registration of parent reported symptoms, diagnoses, medication use, and hospitalizations will be performed. The primary outcome is persistent wheeze or asthma until age 3 years, with predefined analyses of effect modification by maternal genotypes. Secondary outcomes are lower respiratory tract infections, gastrointestinal infections, croup, troublesome lung symptoms, eczema, allergy, bone fractures, developmental milestones, mental health, cognition, and growth until age 3 years. A follow-up on both primary and secondary outcomes is planned after unblinding, from age 3 to 6 years.

Interventions

DIETARY_SUPPLEMENTn-3 fatty acid

Oral intake of 4 capsules per day from week 22-26 in pregnancy to 1 week after delivery

OTHERRape seed oil

Oral intake of 4 capsules per day from week 22-26 in pregnancy to 1 week after delivery

Sponsors

Professor Klaus Bønnelykke
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender
FEMALE
Age
18 Years to 45 Years
Healthy volunteers
Yes

Inclusion criteria

* Pregnant Danish women before week 26 with blood levels of EPA+DHA below 4.7% of total fatty acids * No planned use of fish oil supplementations * No endocrine-, heart-, kidney- or auto-immune disorders * No disorders requiring treatment with blood thinning medication

Design outcomes

Primary

MeasureTime frameDescription
Early childhood asthma/persistent wheeze age 0-3 years3 yearsDefined as either a) parental report of a minimum of 2 wheeze episodes with at least 1 after the child's second birthday and redemption of at least 2 prescriptions of asthma controller medication with at least 1 being after the child's second birthday or b) a minimum of 2 ED visits or hospitalizations due to asthmatic symptoms, and at least 1 of these being after the child's second birthday or c) parental report of physician-diagnosed asthma age 0-3 years Outcome analysis: risk (survival analysis) of persistent wheeze or asthma at age 0-3 years.

Secondary

MeasureTime frameDescription
Atopic/non-atopic wheeze or asthma age 0-3 years3 yearsParental reports of physician diagnosed asthma in combination with eczema and/or allergic rhinitis. Outcome analyses: asthma/persistent wheeze with/without eczema and/or allergic rhinitis (yes/no) by age 3 years. Each subtype is compared with children without asthma.
Troublesome lung symptoms age 0-3 years3 yearsDefined as cough, wheeze or dyspnea severely affecting the well-being of the child for at least 3 consecutive days based on parental reports. Outcome analyses: total no. of episodes with symptoms age 0-3 years.
Wheeze episodes age 0-3 years3 yearsParental reports of wheezing. Outcome analyses: total no. of episodes with wheeze age 0-3 years.
Inhaled bronchodilator use from parental reports age 0-3 years3 yearsOutcome analyses: total no. of days with bronchodilator use age 0-3.
Inhaled bronchodilator prescriptions from medical record checks age 0-3 years3 yearsOutcome analyses: total no. of prescriptions age 0-3.
Asthma controller medication use from parental reports age 0-3 years3 yearsOutcome analyses: total no. of days with use of asthma controller medication age 0-3.
Asthma controller medication prescriptions from medical record checks age 0-3 years3 yearsOutcome analyses: total no. of prescriptions age 0-3.
Asthma hospitalizations or emergency department visits age 0-3 years3 yearsOutcome analyses: total no. of episodes age 0-3 years.
Eczema age 0-3 years3 yearsParental reports of physician-diagnosed eczema and prescribed topical antiinflammatory medication on medical record checks. Outcome analyses: risk (survival analysis) of any eczema age 0-3 years and current eczema (yes/no) by age 3 years.
Food allergy 0-3 years3 yearsParental reports of physician-diagnosed food allergy. Outcome analyses: any food allergy (yes/no) by age 3 years.
Lower respiratory tract infections age 0-3 years3 yearsParental reports of physician-diagnosed bronchiolitis or pneumonia. Outcome analysis: risk (survival analysis) of first lower respiratory tract infection and total no. of lower respiratory tract infections age 0-3 years.
Gastrointestinal infections age 0-3 years3 yearsParental reports. Outcome analyses: risk (survival analysis) of any gastroenteritis episode and total no. of gastroenteritis episodes age 0-3 years.
Croup age 0-3 years3 yearsParental reports of physician diagnosed croup. Outcome analysis: risk (survival analysis) of any croup episode and total no. of croup episodes age 0-3 years.
Fever episodes age 0-3 years3 yearsBased on parental reports. Outcome analyses: total no. of episodes with symptoms age 0-3 years.
Absences from daycare age 0-3 years3 yearsDue to illnesses based on parental reports. Outcome analyses: total no. of absence days age 0-3 years.
Bone fractures age 0-3 years3 yearsAssessed by medical record checks including all radiologically verified fractures of larger long bones (i.e. clavicle, radius, ulna, tibia, fibula, femur and humerus). Outcome analyses: total no. of fractures age 0-3 years.
Developmental milestones age 0-3 years3 yearsMonitored every 6 months until age 3 years by the parents using a registration form based on The Denver Development Index and WHO milestones registration. Outcome analyses: combined assessment of age at achievement across milestones by principal component analysis.
Strength and difficulties at age 3 years3 yearsFrom the Strengths and Difficulties Questionnaire (SDQ), which is a brief behavioral screening questionnaire. Outcome analyses: SDQ scores at age 3 years.
ADHD symptoms at age 3 years3 yearsFrom the ADHD rating scale-IV preschool, a dimensional questionnaire for ADHD symptoms in preschool children. Outcome analyses: ADHD symptom scores at age 3 years.
Asthma controller medication 0-6 years6 yearsFrom redeemed medication prescriptions (inhaled corticosteroids and leukotriene modifiers) based on medical record checks: Outcome analyses: total no. of prescriptions age 0-6 years.
Social behavior assessment at age 3 years3 yearsFrom the Social Responsiveness Scale, Second Edition; a questionnaire for screening for autistic traits: Outcome analyses: Total problem scores at age 3 years.
Psychopathology screening at age 3 years3 yearsFrom the Child Behavior Check List 1,5-5 years; a questionnaire for general screening of preschool psychopathology. Outcome analyses: Total syndrome scales at age 3 years.
Cognitive assessment age 0-3 years3 yearsFrom Behavior Rating Inventory of Executive Function in preschool children; a measurement of executive functions. Outcome analyses: Index values at age 3 years.
BMI and waist circumference age 0-3 years3 yearsFrom parental reports every 6 months. Outcome analyses: development of BMI and waist circumference age 0-3 years and current BMI and waist circumference at age 3.
Persistent wheeze or asthma age 0-6 years6 yearsDefined similarly to the primary outcome Outcome analysis: risk (survival analysis) of persistent wheeze or asthma at age 0-6 years
Current asthma at age 6 years6 yearsDefined similarly to the primary outcome and with symptoms and/or asthma medication use in the last 12 months at age 6. Outcome analyses: Current wheeze or asthma (yes/no) by age 6 years.
Asthma or wheeze yearly prevalence 0-6 years6 yearsDefined as in the primary outcome and current disease defined from parental reports of wheeze and/or asthma medication use. Outcome analyses: Yearly prevalence of wheeze or asthma medication use (yes/no) 0-6 years.
Atopic/non-atopic asthma at age 6 years6 yearsParental reports of physician diagnosed asthma in combination with eczema and/or allergic rhinitis. Outcome analyses: Current asthma with/without eczema and/or allergic rhinitis (yes/no) by age 6 years. Each subtype is compared with children without asthma.
Inhaled bronchodilators age 0-6 years6 yearsFrom redeemed inhaled bronchodilators based on medical record checks. Outcome analyses: total no. of prescriptions age 0-6 years.
Asthma hospitalizations or emergency department visits age 0-6 years6 yearsBased on medical record checks. Outcome analyses: total no. of episodes age 0-6 years.
Eczema age 0-6 years6 yearsBased on parental reports of physician diagnosed eczema. Outcome analyses: risk (survival analysis) of any eczema age 0-6 years and current eczema (yes/no) by age 6 years.
Allergic rhinitis age 0-6 years6 yearsBased on parental reports of physician-diagnosed allergic rhinitis and on medical record checks. Outcome analyses: allergic rhinitis (yes/no) by age 6 years.
Food allergy age 0-6 years6 yearsBased on parental reports of physician-diagnosed food allergy. Outcome analyses: any food allergy (yes/no) by age 6 years.
Lower respiratory tract infections age 0-6 years6 yearsBased on parental reports of physician-diagnosed bronchiolitis or pneumonia. Outcome analysis: risk (survival analysis) of first lower respiratory tract infection and total no. of lower respiratory tract infections age 0-6 years.
Gastrointestinal infections age 0-6 years6 yearsBased on parental reports. Outcome analyses: risk (survival analysis) of any gastroenteritis episode and total no. of gastroenteritis episodes age 0-6 years.
Croup age 0-6 years6 yearsBased on parental reports of physician diagnosed croup. Outcome analysis: risk (survival analysis) of any croup episode and total no. of croup episodes age 0-6 years.
Bone fractures age 0-6 years6 yearsAssessed by medical record checks including all radiologically verified fractures of larger long bones (i.e. clavicle, radius, ulna, tibia, fibula, femur and humerus). Outcome analyses: total no. of fractures age 0-6 years.
Strength and difficulties at age 6 years6 yearsFrom the Strengths and Difficulties Questionnaire (SDQ), which is a brief behavioral screening questionnaire. Outcome analyses: SDQ scores at age 6 years.
Allergic rhinitis age 0-3 years3 yearsBased on parental reports of physician-diagnosed allergic rhinitis. Outcome analyses: allergic rhinitis (yes/no) by age 3 years.
Social behavior assessment at age 6 years6 yearsFrom the Social Responsiveness Scale, Second Edition; a questionnaire for screening for autistic traits. Outcome analyses: Total problem scores at age 6 years.
Psychopathology screening at age 6 years6 yearsFrom the Child Behavior Check List; a questionnaire for general screening of preschool psychopathology. Outcome analyses: Total syndrome scales at age 6 years.
Cognitive assessment age 0-6 years6 yearsFrom Behavior Rating Inventory of Executive Function in preschool children; a measurement of executive functions. Outcome analyses: Index values at age 6 years.
BMI and waist circumference age 0-6 years6 yearsFrom parental reports every 6 months. Outcome analyses: development of BMI and waist circumference age 0-6 years and current BMI and waist circumference at age 6.
ADHD symptoms at age 6 years6 yearsFrom the ADHD rating scale-IV preschool, a dimensional questionnaire for ADHD symptoms in preschool children. Outcome analyses: ADHD symptom scores at age 6 years.

Countries

Denmark

Contacts

Primary ContactKlaus Bønnelykke, PhD
kb@copsac.com+45 38677360
Backup ContactUlrik Ralfkiaer, PhD
administration@dbac.dk+45 38674164

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 5, 2026